499 related articles for article (PubMed ID: 27609505)
1. Managing Hyperkalemia: Stepping Into a New Frontier.
Pham AQ; Sexton J; Wimer D; Rana I; Nguyen T
J Pharm Pract; 2017 Oct; 30(5):557-561. PubMed ID: 27609505
[TBL] [Abstract][Full Text] [Related]
2. Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.
Schaefer JA; Gales MA
Ann Pharmacother; 2016 Jun; 50(6):502-10. PubMed ID: 27009290
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapies for the management of chronic hyperkalemia in the ambulatory care setting.
Henneman A; Guirguis E; Grace Y; Patel D; Shah B
Am J Health Syst Pharm; 2016 Jan; 73(2):33-44. PubMed ID: 26721532
[TBL] [Abstract][Full Text] [Related]
4. Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF
Mayo Clin Proc; 2020 Feb; 95(2):339-354. PubMed ID: 31668450
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
Takkar C; Nassar T; Qunibi W
Expert Opin Pharmacother; 2021 Jan; 22(1):19-28. PubMed ID: 32892634
[TBL] [Abstract][Full Text] [Related]
6. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.
Tamargo J; Caballero R; Delpón E
Cardiovasc Drugs Ther; 2018 Feb; 32(1):99-119. PubMed ID: 29372448
[TBL] [Abstract][Full Text] [Related]
7. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
Santoro A; Mandreoli M
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
[TBL] [Abstract][Full Text] [Related]
8. Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.
Athyros VG; Sachinidis AG; Zografou I; Simoulidou E; Piperidou A; Stavropoulos N; Karagiannis A
Curr Pharm Des; 2018; 24(46):5542-5547. PubMed ID: 30848186
[TBL] [Abstract][Full Text] [Related]
9. Sodium zirconium cyclosilicate reconciles management of hyperkalemia and continuity of renin-angiotensin-aldosterone system inhibitors: a retrospective observational study.
Kimura W; Minatoguchi S; Mizuno T; Koide S; Hayashi H; Hasegawa M; Inaguma D; Tsuboi N
J Nephrol; 2024 Jan; 37(1):171-179. PubMed ID: 37608241
[TBL] [Abstract][Full Text] [Related]
10. Advances in treatment of hyperkalemia in chronic kidney disease.
Sarafidis PA; Georgianos PI; Bakris GL
Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia.
Meaney CJ; Beccari MV; Yang Y; Zhao J
Pharmacotherapy; 2017 Apr; 37(4):401-411. PubMed ID: 28122118
[TBL] [Abstract][Full Text] [Related]
12. New drugs to prevent and treat hyperkalemia.
Lepage L; Desforges K; Lafrance JP
Curr Opin Nephrol Hypertens; 2016 Nov; 25(6):524-528. PubMed ID: 27584929
[TBL] [Abstract][Full Text] [Related]
13. Sodium Zirconium Cyclosilicate (ZS-9): A Novel Agent for the Treatment of Hyperkalemia.
Linder KE; Krawczynski MA; Laskey D
Pharmacotherapy; 2016 Aug; 36(8):923-33. PubMed ID: 27393581
[TBL] [Abstract][Full Text] [Related]
14. Novel Agents for the Prevention and Management of Hyperkalemia.
McCullough PA; Costanzo MR; Silver M; Spinowitz B; Zhang J; Lepor NE
Rev Cardiovasc Med; 2015; 16(2):140-55. PubMed ID: 26198561
[TBL] [Abstract][Full Text] [Related]
15. Patiromer: a clinical review.
Montaperto AG; Gandhi MA; Gashlin LZ; Symoniak MR
Curr Med Res Opin; 2016; 32(1):155-64. PubMed ID: 26456884
[TBL] [Abstract][Full Text] [Related]
16. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.
Rafique Z; Peacock WF; LoVecchio F; Levy PD
Expert Opin Pharmacother; 2015; 16(11):1727-34. PubMed ID: 26159448
[TBL] [Abstract][Full Text] [Related]
17. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management.
Krishnan SK; Lepor NE
Rev Cardiovasc Med; 2016; 17 Suppl 1():S9-S21. PubMed ID: 27725623
[TBL] [Abstract][Full Text] [Related]
18. [Hyperkalemia - current therapuetic strategies].
Głogowski T; Wojtaszek E
Wiad Lek; 2016; 69(5):745-748. PubMed ID: 28033600
[TBL] [Abstract][Full Text] [Related]
19. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
20. Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA; Gross C; Yuan J; Conrad A; Pergola PE
J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):524-531. PubMed ID: 30103622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
